TY  - JOUR
PY  - 2015//
TI  - Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
JO  - Psychological medicine
A1  - Murrough, J. W.
A1  - Soleimani, L.
A1  - DeWilde, K. E.
A1  - Collins, K. A.
A1  - Lapidus, K. A.
A1  - Iacoviello, B. M.
A1  - Lener, M.
A1  - Kautz, M.
A1  - Kim, J.
A1  - Stern, J. B.
A1  - Price, R. B.
A1  - Perez, A. M.
A1  - Brallier, J. W.
A1  - Rodriguez, G. J.
A1  - Goodman, W. K.
A1  - Iosifescu, D. V.
A1  - Charney, Dennis S.
SP  - 3571
EP  - 3580
VL  - 45
IS  - 16
N2  - BACKGROUND: Suicide is a devastating public health problem and very few biological treatments have been found to be effective for quickly reducing the intensity of suicidal ideation (SI). We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression. <br><br>METHOD: We conducted a randomized, controlled trial of ketamine in patients with mood and anxiety spectrum disorders who presented with clinically significant SI (n = 24). Patients received a single infusion of ketamine or midazolam (as an active placebo) in addition to standard of care. SI measured using the Beck Scale for Suicidal Ideation (BSI) 24 h post-treatment represented the primary outcome. Secondary outcomes included the Montgomery-Asberg Depression Rating Scale - Suicidal Ideation (MADRS-SI) score at 24 h and additional measures beyond the 24-h time-point. <br><br>RESULTS: The intervention was well tolerated and no dropouts occurred during the primary 7-day assessment period. BSI score was not different between the treatment groups at 24 h (p = 0.32); however, a significant difference emerged at 48 h (p = 0.047). MADRS-SI score was lower in the ketamine group compared to midazolam group at 24 h (p = 0.05). The treatment effect was no longer significant at the end of the 7-day assessment period. <br><br>CONCLUSIONS: The current findings provide initial support for the safety and tolerability of ketamine as an intervention for SI in patients who are at elevated risk for suicidal behavior. Larger, well-powered studies are warranted.<p />  <p>Language: en</p>
LA  - en
SN  - 0033-2917
UR  - http://dx.doi.org/10.1017/S0033291715001506
ID  - ref1
ER  -